Seeing Is Believing
Currently out of the existing stock ratings of Karl Chalabala, 9 are a BUY (90%), 1 are a HOLD (10%).
Analyst Karl Chalabala, carries an average stock price target met ratio of 16.67% that have a potential upside of 13.23% achieved within 455 days. Previously, Karl Chalabala worked at UBS, STIFEL, CANACCORD.
Karl Chalabala’s has documented 18 price targets and ratings displayed on 6 stocks. The coverage was on Energy, Healthcare sectors.
Most recent stock forecast was given on FOLD, Amicus Therapeutics at 10-May-2024.
Analyst best performing recommendations are on EQT (EQT).
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 01-Apr-2025
$68
$15.55 (29.65%)
$72
Hold Since 22-May-2025
$54
$1.55 (2.96%)
$63
Buy Since 19-Oct-2022
$73
$20.55 (39.18%)
$75
17 days ago
(29-Sep-2026)
12/22 (54.55%)
$24.12 (49.35%)
379
Buy Since 06-Dec-2024
$68
$15.55 (29.65%)
$67
23 days ago
(23-Sep-2026)
10/14 (71.43%)
$16.94 (33.18%)
281
Buy Since 15-Apr-2025
$71
$18.55 (35.37%)
$72
29 days ago
(17-Sep-2026)
7/13 (53.85%)
$20.65 (41.01%)
124